The same radioconjugate was tested in NOG mice bearing BT-474 (HER2 +) and MDA-MB-231 tumours, reaching the uptake of around 47% ID/g in HER2 + tumour with high SD of 32% ID/g and around 9.5% ID/g in HER2- tumour (Kang et al. 2022). Here, ERBB2 is linked to neoplasm.